国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2014年
2期
80-83
,共4页
白庆双%李宁%方佩华%吴彩兰%葛建萍%张伟
白慶雙%李寧%方珮華%吳綵蘭%葛建萍%張偉
백경쌍%리저%방패화%오채란%갈건평%장위
受体,促甲状腺素释放激素%酶联免疫吸附测定%甲状腺疾病
受體,促甲狀腺素釋放激素%酶聯免疫吸附測定%甲狀腺疾病
수체,촉갑상선소석방격소%매련면역흡부측정%갑상선질병
Receptor,thyrotropin-releasing hormone%Enzyme-linked immunosorbent assay%Thyroid diseases
目的 探讨促甲状腺激素受体抗体(TRAb)水平对健康人和不同甲状腺疾病患者的临床意义.方法 分别以重组人促甲状腺激素受体(TSHR)膜外区氨基(N)端蛋白和羧基(C)端蛋白作为抗原建立N法和C法,分别检测89名健康者(正常对照组)和254例各种甲状腺疾病患者的血清TRAb水平,组间血清TRAb水平比较采用方差分析,组间阳性率比较采用x2检验.结果 应用N法检测发现:89名健康者405 nm处的光吸收值((x)±s)为0.511±0.135,阳性切限值((x)±2s)为0.789,阳性率为4.5％(4/89);初发Graves病(毒性弥漫性甲状腺肿)患者及Hashimoto甲状腺炎伴甲状腺功能减退症(简称甲减)患者405 nm处的光吸收值((x)±s)分别为:0.95±0.30、0.61±0.22,高于健康者(F=2.4851和2.0763,P均＜0.05);N法对初发Graves病患者、治疗中的Graves 病患者、Graves病治疗恢复期患者、Hashimoto甲状腺炎伴甲减患者检测的阳性率分别为73.2％、55.9％、32.1％、45.0％,与正常对照组阳性率之间的差异均有统计学意义(x2=68.55、56.45、20.71和25.51,P均＜0.05);初发Graves病患者阳性检出率高于Hashimoto甲状腺炎伴甲减患者(x2=4.63,P＜0.05),初发Graves病患者与Graves病治疗恢复期患者阳性率之间的差异有统计学意义(x2=15.94,P＜0.05).应用C法检测发现:89名健康者405 nm处的光吸收值((x)±s)为0.507±0.142,阳性切限值((x)+2s)为0.791,阳性率为3.4％(3/89);Hashimoto甲状腺炎伴甲减患者及初发Graves病患者405 nm处的光吸收值((x)±s)为1.18±0.25、0.78±0.25,明显高于健康者(F=3.8164和2.4539,P＜0.05);C法对Hashimoto甲状腺炎伴甲减患者、初发Graves病患者、治疗中的Graves病患者、Graves病治疗恢复期患者检测的阳性率分别为:75.0％、46.3％、23.6％、16.1％,与正常对照组阳性率之间的差异均有统计学意义(x2=66.34、36.87、15.79和7.30,P均＜0.05);Hashimoto甲状腺炎伴甲减患者阳性检出率明显高于其他患者(x2=4.48、19.70和23.68,P均＜0.05).结论 应用N法和C法检测Graves病和Hashimoto患者血清TRAb水平均有重要意义,可用于临床Graves病和Hashimoto甲状腺炎伴甲减患者的诊断、治疗及疗效的评估.
目的 探討促甲狀腺激素受體抗體(TRAb)水平對健康人和不同甲狀腺疾病患者的臨床意義.方法 分彆以重組人促甲狀腺激素受體(TSHR)膜外區氨基(N)耑蛋白和羧基(C)耑蛋白作為抗原建立N法和C法,分彆檢測89名健康者(正常對照組)和254例各種甲狀腺疾病患者的血清TRAb水平,組間血清TRAb水平比較採用方差分析,組間暘性率比較採用x2檢驗.結果 應用N法檢測髮現:89名健康者405 nm處的光吸收值((x)±s)為0.511±0.135,暘性切限值((x)±2s)為0.789,暘性率為4.5％(4/89);初髮Graves病(毒性瀰漫性甲狀腺腫)患者及Hashimoto甲狀腺炎伴甲狀腺功能減退癥(簡稱甲減)患者405 nm處的光吸收值((x)±s)分彆為:0.95±0.30、0.61±0.22,高于健康者(F=2.4851和2.0763,P均＜0.05);N法對初髮Graves病患者、治療中的Graves 病患者、Graves病治療恢複期患者、Hashimoto甲狀腺炎伴甲減患者檢測的暘性率分彆為73.2％、55.9％、32.1％、45.0％,與正常對照組暘性率之間的差異均有統計學意義(x2=68.55、56.45、20.71和25.51,P均＜0.05);初髮Graves病患者暘性檢齣率高于Hashimoto甲狀腺炎伴甲減患者(x2=4.63,P＜0.05),初髮Graves病患者與Graves病治療恢複期患者暘性率之間的差異有統計學意義(x2=15.94,P＜0.05).應用C法檢測髮現:89名健康者405 nm處的光吸收值((x)±s)為0.507±0.142,暘性切限值((x)+2s)為0.791,暘性率為3.4％(3/89);Hashimoto甲狀腺炎伴甲減患者及初髮Graves病患者405 nm處的光吸收值((x)±s)為1.18±0.25、0.78±0.25,明顯高于健康者(F=3.8164和2.4539,P＜0.05);C法對Hashimoto甲狀腺炎伴甲減患者、初髮Graves病患者、治療中的Graves病患者、Graves病治療恢複期患者檢測的暘性率分彆為:75.0％、46.3％、23.6％、16.1％,與正常對照組暘性率之間的差異均有統計學意義(x2=66.34、36.87、15.79和7.30,P均＜0.05);Hashimoto甲狀腺炎伴甲減患者暘性檢齣率明顯高于其他患者(x2=4.48、19.70和23.68,P均＜0.05).結論 應用N法和C法檢測Graves病和Hashimoto患者血清TRAb水平均有重要意義,可用于臨床Graves病和Hashimoto甲狀腺炎伴甲減患者的診斷、治療及療效的評估.
목적 탐토촉갑상선격소수체항체(TRAb)수평대건강인화불동갑상선질병환자적림상의의.방법 분별이중조인촉갑상선격소수체(TSHR)막외구안기(N)단단백화최기(C)단단백작위항원건립N법화C법,분별검측89명건강자(정상대조조)화254례각충갑상선질병환자적혈청TRAb수평,조간혈청TRAb수평비교채용방차분석,조간양성솔비교채용x2검험.결과 응용N법검측발현:89명건강자405 nm처적광흡수치((x)±s)위0.511±0.135,양성절한치((x)±2s)위0.789,양성솔위4.5％(4/89);초발Graves병(독성미만성갑상선종)환자급Hashimoto갑상선염반갑상선공능감퇴증(간칭갑감)환자405 nm처적광흡수치((x)±s)분별위:0.95±0.30、0.61±0.22,고우건강자(F=2.4851화2.0763,P균＜0.05);N법대초발Graves병환자、치료중적Graves 병환자、Graves병치료회복기환자、Hashimoto갑상선염반갑감환자검측적양성솔분별위73.2％、55.9％、32.1％、45.0％,여정상대조조양성솔지간적차이균유통계학의의(x2=68.55、56.45、20.71화25.51,P균＜0.05);초발Graves병환자양성검출솔고우Hashimoto갑상선염반갑감환자(x2=4.63,P＜0.05),초발Graves병환자여Graves병치료회복기환자양성솔지간적차이유통계학의의(x2=15.94,P＜0.05).응용C법검측발현:89명건강자405 nm처적광흡수치((x)±s)위0.507±0.142,양성절한치((x)+2s)위0.791,양성솔위3.4％(3/89);Hashimoto갑상선염반갑감환자급초발Graves병환자405 nm처적광흡수치((x)±s)위1.18±0.25、0.78±0.25,명현고우건강자(F=3.8164화2.4539,P＜0.05);C법대Hashimoto갑상선염반갑감환자、초발Graves병환자、치료중적Graves병환자、Graves병치료회복기환자검측적양성솔분별위:75.0％、46.3％、23.6％、16.1％,여정상대조조양성솔지간적차이균유통계학의의(x2=66.34、36.87、15.79화7.30,P균＜0.05);Hashimoto갑상선염반갑감환자양성검출솔명현고우기타환자(x2=4.48、19.70화23.68,P균＜0.05).결론 응용N법화C법검측Graves병화Hashimoto환자혈청TRAb수평균유중요의의,가용우림상Graves병화Hashimoto갑상선염반갑감환자적진단、치료급료효적평고.
Objective To investigate the level of the thyrotropin recepter antibody (TRAb) in healthy people and patients with different types of thyroid disease,and discuss its clinical significance.Methods Recombinant human thyroid stimulating hormone receptor (TSHR)-ecd N-terminal fragment was used in N method and C-terminal fragment was used in C method as antigens respectively.The serum level of TRAb was measured in 89 healthy people and 254 patients with different types of thyroid disease respectively.The serum levels of TRAb comparison and positive rates comparison between groups were tested by analysis of variance and chi-square test respectively.Results The result of N method:the 405nm light absorption value ((x)±s) in healthy people was 0.511 ±0.135 with a cut-off value ((x)+2s) of 0.789.The positive rate was 4.5％ (4/89).The 405 nm light absorption value((x)±s) in patients with incipient Graves (diffuse toxic goiter) and Hashimoto thyroiditis with hypothyroidism was 0.95±0.30,0.61±0.22 respectively,which was higher than that in healthy people (F=2.4851 and 2.0763,both P＜0.05).The positive rate in incipient Graves disease,Graves disease with treatment,Graves disease patients in convalescence stage and Hashimoto thyroiditis with hypothyroidism was 73.2％,55.9％,32.1％,45.0％,respectively.There were significant differences between the above groups and the normal control group (x2=68.55,56.45,20.71 and 25.51,all P＜0.05).The positive rate was significantly higher in incipient Graves disease patients than Hashimoto thyroiditis with hypothyroidism patients (x2=4.63,P＜0.05).There was significant difference in the positive rate between incipient Graves disease and Graves disease patients in convalescence stage (x2=15.94,P＜0.05).The result of C method:the 405 nm light absorption value ((x)±s) in healthy people was 0.507±0.142 with a cut-off value((x)+2s) of 0.791.The positive rate was 3.4％ (3/89).The 405 nm light absorption value((x)±s) in Hashimoto thyroiditis with hypothyroidism patients and incipient Graves disease patients was 1.18±0.25,0.78±0.25,respectively,which was significantly higher than that in healthy people (F=3.8164,2.4539,P＜0.05).The positive rate in Hashimoto thyroiditis with hypothyroidism,incipient Graves disease,Graves disease with treatment,Graves disease patients in convalescence stage was 75.0％,46.3％,23.6％,16.1％,respectively.There were significant differences among the above groups and the normal control group ((x)=66.34,36.87,15.79,7.30,all P＜0.05).The positive rate was significantly higher in Hashimoto thyroiditis with hypothyroidism than other groups (x2=4.48,19.70,23.68,all P＜0.05).Conclusions The N method and C method had important significance for detecting the serum level of TRAb in Graves disease and Hashimoto thyroiditis with hypothyroidism.It may be used in clinical diagnosis,treatment and curative effect evaluation for Graves disease and Hashimoto thyroiditis with hypothyroidism.
